Abstract
Cytomegalovirus (CMV) is the most common congenital infection worldwide. Twenty percent of congenital CMV (cCMV) infections result in permanent disability, including hearing loss, cognitive deficits, cerebral palsy, and vision impairment, and 4% of cases result in death. Early recognition and diagnosis are imperative, as both antiviral treatment and non-pharmaceutical interventions can improve patient outcomes by reducing hearing loss, other symptomology, and overall disease severity. Specifically, evidence of effective therapy for symptomatic infants and, more recently, reduced fetal transmission following treatment of maternal primary infection may support expanded screening activities. Here, we present an overview of the clinical presentation, treatment and prevention of maternal CMV and cCMV infection. We discuss in detail new diagnostic methods for early and retrospective detection of congenital and maternal primary infections. Finally, we review proposed neonatal and prenatal screening strategies. Clinical laboratories should be aware of the latest clinical studies, the changing diagnostic landscape, and laboratory practices for cCMV and maternal CMV infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.